ESR1 and cancer: The low relapse-free survival rates associated withMALAT1 overexpression were also characteristic of patients with the ER-negativeprofile of tumor expression (HR = 2.83; 95% CI 1.02–7.83; p= 0.045) and for the group of patients having the luminal subtypes ofbreast cancer (ER+) and receiving tamoxifen therapy (HR = 2.56; 95% CI1.04–6.0; p = 0.034) [62].